GeneDx Announced as Sequencing Partner for Sunshine Genetics Act Pilot
Source: JGI/Jamie Grill / Getty Images Genetic sequencing and diagnostics company GeneDx announced this week that it would…
GeneDx to Partner with Florida’s Sunshine Genetics Network, Launching Nation’s First State-Backed Genomic Newborn Screening Program
Florida Institute for Pediatric Rare Diseases and Representative Adam Anderson ushering in a new era of preventative care…
Only four people in Australia have been diagnosed with rare genetic disease CHOPS
Isla Steed is your fairly typical teenager, according to her mum. The 14-year-old is “a stubborn little person”…
NLRP3 inflammasome and hearing loss: from mechanisms to therapies | Journal of Neuroinflammation
Sensorineural hearing loss (SNHL) affects approximately 1.5 billion people globally. Approximately 430 million of these patients require rehabilitation…
Knowing patient’s genetic make-up may change the way medicines are prescribed
SINGAPORE – Not all medicines work the same way on every patient, and part of the answer lies…
Acadia Pharmaceuticals drug for rare genetic condition fails late-stage study
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Developments in diagnostic and surgical techniques in children with sagittal suture craniosynostosis: a systematic review spanning the last 30 years | Orphanet Journal of Rare Diseases
Literature search and study selection An initial search using the search terms related to the operative technique yielded…
Global Pharmaceutical Market Projected to Hit $2.2 Trillion by 2029
BCC Research LLC “Driven by Innovation in Biologics and Expanding Therapeutic Applications, the Global Pharmaceutical Drugs Market Continues…
Sarepta will stop shipping Elevidys, Duchenne gene therapy
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting move
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…